Skip to main content

Menu

Select a tool from the sidebar

Create your free account now!

Sign in to customize and use tools on the sidebar.

Sign InCreate free account
Vertex Pharmaceuticals Incorporated logo
VRTX
Vertex Pharmaceuticals Incorporated
20:00:00
451.63 $
0.0000 (%0.00)
Previous Close: 458.99
Day Low₺450.39
Day High₺464.98
Bid
Ask
Overview
Technicals
Financial Statements
Comments
Archive

VRTX: Vertex Pharmaceuticals Incorporated Financials

Vertex Pharmaceuticals Incorporated Income Statement

Total revenue
Net income
Gross margin TTM
85.03%
Operating margin TTM
39.43%
Net profit margin TTM
32.74%
Return on investment TTM
21.18%
Period end31/12/202531/12/202431/12/202331/12/2022
Total revenue12,074,600,00011,020,100,0009,869,200,0008,930,700,000
Operating income4,760,700,000-232,900,0003,832,000,0004,307,400,000
Net income3,953,200,000-535,600,0003,619,600,0003,322,000,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Total revenue12,074,600,00011,020,100,0009,869,200,0008,930,700,000
Cost of revenue1,807,100,0001,530,500,0001,262,200,0001,080,300,000
Gross profit10,267,500,0009,489,600,0008,607,000,0007,850,400,000
Research and development expenses3,753,700,0003,630,300,0003,162,900,0002,655,800,000
General and administrative expenses0000
Selling and marketing expenses0000
Selling, general and administrative expenses1,753,100,0001,464,300,0001,136,600,000944,700,000
Other expenses04,627,900,000475,500,000-57,500,000
Operating expenses5,506,800,0009,722,500,0004,775,000,0003,543,000,000
Cost and expenses7,313,900,00011,253,000,0006,037,200,0004,623,300,000
Net interest income477,600,000567,500,000570,600,00089,800,000
Interest income490,900,000598,100,000614,700,000144,600,000
Interest expense13,300,00030,600,00044,100,00054,800,000
Depreciation and amortization207,200,000205,800,000181,300,000148,300,000
EBITDA4,863,700,000486,300,0004,605,200,0004,435,500,000
EBIT4,656,500,000279,100,0004,423,900,0004,287,200,000
Non-operating income (excl. interest)104,200,000-512,000,000-591,900,00020,200,000
Operating income4,760,700,000-232,900,0003,832,000,0004,307,400,000
Total other income/expenses (net)-117,500,000481,400,000547,800,000-75,000,000
Income before tax4,643,200,000248,500,0004,379,800,0004,232,400,000
Income tax expense690,000,000784,100,000760,200,000910,400,000
Net income from continuing operations3,953,200,000-535,600,0003,619,600,0003,322,000,000
Net income from discontinued operations0000
Other adjustments to net income0000
Net income3,953,200,000-535,600,0003,619,600,0003,322,000,000
Net income deductions0000
Bottom line net income3,953,200,000-535,600,0003,619,600,0003,322,000,000
EPS15-21413
Diluted EPS15-21413
Weighted average shares outstanding255,700,000257,500,000257,700,000256,100,000
Weighted average diluted shares outstanding258,000,000257,900,000260,500,000259,100,000

Vertex Pharmaceuticals Incorporated Balance Sheet

Total assets
Total liabilities & equity
Liquidity ratio MRQ
—
Current ratio MRQ
—
Long-term debt / assets MRQ
1,846,500,000%
Total debt / assets MRQ
—
Period end31/12/202531/12/202431/12/202331/12/2022
Total assets26,142,800,00022,533,200,00022,730,200,00018,150,900,000
Total liabilities7,477,000,0006,123,600,0005,149,800,0004,238,200,000
Total equity18,665,800,00016,409,600,00017,580,400,00013,912,700,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Cash and cash equivalents5,087,800,0004,569,600,00010,369,100,00010,504,000,000
Short-term investments1,523,300,0001,546,300,000849,200,000274,500,000
Cash and short-term investments6,611,100,0006,115,900,00011,218,300,00010,778,500,000
Net receivables2,052,800,0001,609,400,0001,563,400,0001,442,200,000
Accounts receivable2,052,800,0001,609,400,0001,563,400,0001,442,200,000
Other receivables0000
Inventory1,686,800,0001,205,400,000738,800,000460,600,000
Prepaid expenses101,700,000459,200,000537,600,000431,600,000
Other current assets748,600,000206,500,00086,100,000121,900,000
Total current assets11,201,000,0009,596,400,00014,144,200,00013,234,800,000
Property, plant and equipment (net)3,083,000,0002,584,600,0001,452,900,0001,455,800,000
Goodwill1,088,000,0001,088,000,0001,088,000,0001,088,000,000
Intangible assets424,200,000825,900,000839,900,000603,600,000
Goodwill and intangible assets1,512,200,0001,913,900,0001,927,900,0001,691,600,000
Long-term investments5,806,500,0005,107,900,0002,497,800,000112,200,000
Tax assets3,397,700,0002,331,100,0001,812,100,0001,246,900,000
Other non-current assets1,142,400,000999,300,000895,300,000409,600,000
Total non-current assets14,941,800,00012,936,800,0008,586,000,0004,916,100,000
Other assets0000
Total assets26,142,800,00022,533,200,00022,730,200,00018,150,900,000
Total payables461,700,000413,000,000924,500,000642,200,000
Accounts payable461,700,000413,000,000364,900,000303,900,000
Other payables00559,600,000338,300,000
Accrued expenses397,700,000352,100,0002,318,200,0001,788,400,000
Short-term debt82,800,00092,300,00000
Capital lease obligations (current)0083,700,00089,400,000
Tax payables0161,100,00099,500,000123,300,000
Deferred revenue171,800,000206,800,000170,300,000159,600,000
Other current liabilities2,747,200,0002,500,400,00050,700,00062,500,000
Total current liabilities3,861,200,0003,564,600,0003,547,400,0002,742,100,000
Long-term debt1,846,500,000000
Capital lease obligations (non-current)1,953,200,0001,657,200,000724,700,000810,300,000
Deferred revenue (non-current)0000
Deferred tax liabilities (non-current)1,305,700,000000
Other non-current liabilities-1,489,600,000901,800,000877,700,000685,800,000
Total non-current liabilities3,615,800,0002,559,000,0001,602,400,0001,496,100,000
Other liabilities0000
Capital lease obligations1,953,200,0001,657,200,000808,400,000899,700,000
Total liabilities7,477,000,0006,123,600,0005,149,800,0004,238,200,000
Treasury stock0000
Preferred stock0000
Common stock2,500,0002,600,0002,600,0002,600,000
Retained earnings13,560,000,0009,606,800,00010,142,400,0006,522,800,000
Additional paid-in capital5,119,200,0006,672,400,0007,449,700,0007,386,500,000
Accumulated other comprehensive income/loss-15,900,000127,800,000-14,300,000800,000
Other stockholders' equity0000
Total stockholders' equity18,665,800,00016,409,600,00017,580,400,00013,912,700,000
Total equity18,665,800,00016,409,600,00017,580,400,00013,912,700,000
Minority interest0000
Total liabilities and total equity26,142,800,00022,533,200,00022,730,200,00018,150,900,000
Total investments7,329,800,0006,654,200,0003,347,000,000386,700,000
Total debt3,882,500,0001,749,500,000808,400,000899,700,000
Net debt-1,205,300,000-2,820,100,000-9,560,700,000-9,604,300,000

Vertex Pharmaceuticals Incorporated Cash Flow Statement

Cash from operations
Cash from investing
Cash flow / share TTM
—
Revenue / share TTM
—
Operating cash flow TTM
—
Period end31/12/202531/12/202431/12/202331/12/2022
Cash from operations3,631,400,000-492,600,0003,537,300,0004,129,900,000
Cash from investing-945,400,000-3,770,000,000-3,141,700,000-321,100,000
Cash from financing-2,261,300,000-1,494,900,000-562,200,000-67,700,000
Net change in cash515,600,000-5,800,100,000-139,700,0003,711,900,000

All line items

Line item31/12/202531/12/202431/12/202331/12/2022
Net income3,953,200,000-535,600,0003,619,600,0003,322,000,000
Depreciation and amortization209,800,000207,200,000181,300,000148,300,000
Deferred income tax-510,800,000-348,800,000-536,500,000-275,900,000
Stock-based compensation685,900,000698,500,000581,200,000491,300,000
Change in working capital-1,199,100,000-514,800,000-265,700,000340,800,000
Accounts receivable-347,300,000-99,300,000-84,100,000-358,600,000
Inventory-524,200,000-517,300,000-322,900,000-136,400,000
Accounts payable36,800,00049,500,00048,700,000120,800,000
Other working capital-364,400,00052,300,00092,600,000715,000,000
Other non-cash items492,400,000900,000-42,600,000103,400,000
Net cash from operating activities3,631,400,000-492,600,0003,537,300,0004,129,900,000
Investments in property, plant and equipment-437,600,000-297,700,000-200,400,000-204,700,000
Acquisitions (net)000-295,900,000
Purchases of investments-6,396,500,000-7,696,200,000-3,786,500,000-692,700,000
Sales/maturities of investments5,913,400,0004,465,600,000934,200,000920,000,000
Other investing activities-24,700,000-241,700,000-89,000,000-47,800,000
Net cash from investing activities-945,400,000-3,770,000,000-3,141,700,000-321,100,000
Net debt issuance-5,400,000-33,600,000-44,900,000-85,500,000
Long-term net debt issuance-5,400,000-33,600,000-44,900,000-85,500,000
Short-term net debt issuance0000
Net stock issuance-1,889,700,000-1,062,500,000-293,000,00014,300,000
Net common stock issuance-1,889,700,000-1,062,500,000-293,000,00014,300,000
Common stock issuance127,700,000114,600,000134,600,000186,300,000
Common stock repurchased-2,017,400,000-1,177,100,000-427,600,000-172,000,000
Net preferred stock issuance0000
Net dividends paid0000
Common dividends paid0000
Preferred dividends paid0000
Other financing activities-366,200,000-398,800,000-224,300,0003,500,000
Net cash from financing activities-2,261,300,000-1,494,900,000-562,200,000-67,700,000
Effect of FX changes on cash90,900,000-42,600,00026,900,000-29,199,999
Net change in cash515,600,000-5,800,100,000-139,700,0003,711,900,000
Cash at end of period5,087,800,0004,572,200,00010,372,300,00010,512,000,000
Cash at beginning of period4,572,200,00010,372,300,00010,512,000,0006,800,100,000
Operating cash flow3,631,400,000-492,600,0003,537,300,0004,129,900,000
Capital expenditure-437,600,000-297,700,000-258,400,000-204,700,000
Free cash flow3,193,800,000-790,300,0003,278,900,0003,925,200,000
Income taxes paid1,566,700,0001,082,100,0001,677,300,0001,057,800,000
Interest paid12,400,00030,500,00043,100,00052,300,000